Stock MORF MORPHIC HOLDING, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Morphic Holding, Inc.

Equities

MORF

US61775R1059

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
28.07 USD +0.32% Intraday chart for Morphic Holding, Inc. +0.29% -2.80%
04-25 Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-19 Morphic Holding Names Simon Cooper as Chief Medical Officer MT

Business Summary

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Number of employees: 124

Managers

Managers TitleAgeSince
Praveen Tipirneni CEO
 Chief Executive Officer 55 30/06/15
Bruce Rogers PSD
 President 55 31/12/15
Marc Schegerin DFI
 Director of Finance/CFO 48 05/04/20
Blaise Lippa CTO
 Chief Tech/Sci/R&D Officer - 31/05/15
Brihad Abhyankar CTO
 Chief Tech/Sci/R&D Officer - 05/04/22
Joanne Gibbons LAW
 General Counsel - 17/05/22
William DeVaul LAW
 General Counsel 53 31/01/19
Aaron Pelta PRN
 Corporate Officer/Principal - 31/12/18
Robert Farrell AUD
 Comptroller/Controller/Auditor 58 31/05/15

Members of the board

Members of the board TitleAgeSince
Timothy Springer FOU
 Founder 76 31/07/14
Norbert W. Bischofberger BRD
 Director/Board Member 68 31/05/19
Joseph Slattery BRD
 Director/Board Member 59 30/04/19
Amir Nashat BRD
 Director/Board Member 51 31/05/17
Susannah Gray BRD
 Director/Board Member 63 26/04/21
Martin Edwards BRD
 Director/Board Member 68 03/12/20
Gustav Christensen CHM
 Chairman 76 31/03/16
Nisha Nanda BRD
 Director/Board Member 49 18/08/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 50,093,588 41,582,883 ( 83.01 %) 0 83.01 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
13.56 %
6,783,303 13.56 % 239 M $
Timothy Springer
9.295 %
4,650,925 9.295 % 164 M $
Point72 Asset Management LP
9.175 %
4,591,000 9.175 % 162 M $
Wellington Management Co. LLP
6.750 %
3,377,310 6.750 % 119 M $
BlackRock Advisors LLC
6.260 %
3,132,471 6.260 % 110 M $
Tas Partners LLC
5.534 %
2,768,893 5.534 % 97 M $
STATE STREET CORPORATION
5.124 %
2,564,058 5.124 % 90 M $
Vanguard Fiduciary Trust Co.
4.639 %
2,321,046 4.639 % 82 M $
T. Rowe Price International Ltd.
4.442 %
2,222,628 4.442 % 78 M $
Artal Group SA
4.273 %
2,138,188 4.273 % 75 M $

Company contact information

Morphic Holding, Inc.

35 Gatehouse Drive A2

02451, Waltham

+781 996 0955

address Morphic Holding, Inc.(MORF)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Morphic Holding, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
28.07 USD
Average target price
56 USD
Spread / Average Target
+99.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MORPHIC HOLDING, INC. Stock Morphic Holding, Inc.
-2.80% 1.41B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MORF Stock
  4. Company Morphic Holding, Inc.